CA2690067C - A diagnostic method by measuring the levels of heparin-binding protein - Google Patents

A diagnostic method by measuring the levels of heparin-binding protein Download PDF

Info

Publication number
CA2690067C
CA2690067C CA2690067A CA2690067A CA2690067C CA 2690067 C CA2690067 C CA 2690067C CA 2690067 A CA2690067 A CA 2690067A CA 2690067 A CA2690067 A CA 2690067A CA 2690067 C CA2690067 C CA 2690067C
Authority
CA
Canada
Prior art keywords
hbp
individual
severe sepsis
risk
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2690067A
Other languages
English (en)
French (fr)
Other versions
CA2690067A1 (en
Inventor
Lars Bjorck
Bertil Christensson
Heiko Herwald
Adam Linder
Per Akesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38331957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2690067(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of CA2690067A1 publication Critical patent/CA2690067A1/en
Application granted granted Critical
Publication of CA2690067C publication Critical patent/CA2690067C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2690067A 2007-06-12 2008-06-12 A diagnostic method by measuring the levels of heparin-binding protein Active CA2690067C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0711327.7A GB0711327D0 (en) 2007-06-12 2007-06-12 Diagnostic method
GB0711327.7 2007-06-12
PCT/EP2008/004743 WO2008151808A1 (en) 2007-06-12 2008-06-12 Diagnostic method

Publications (2)

Publication Number Publication Date
CA2690067A1 CA2690067A1 (en) 2008-12-18
CA2690067C true CA2690067C (en) 2023-09-19

Family

ID=38331957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2690067A Active CA2690067C (en) 2007-06-12 2008-06-12 A diagnostic method by measuring the levels of heparin-binding protein

Country Status (16)

Country Link
US (3) US8518648B2 (https=)
EP (1) EP2129391B1 (https=)
JP (1) JP5166522B2 (https=)
KR (1) KR101563997B1 (https=)
CN (2) CN101687023B (https=)
AT (1) ATE548050T1 (https=)
AU (1) AU2008261252B2 (https=)
BR (1) BRPI0812875B8 (https=)
CA (1) CA2690067C (https=)
DK (1) DK2129391T3 (https=)
ES (1) ES2380875T3 (https=)
GB (1) GB0711327D0 (https=)
PL (1) PL2129391T3 (https=)
PT (1) PT2129391E (https=)
SI (1) SI2129391T1 (https=)
WO (1) WO2008151808A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
JP5488885B2 (ja) * 2009-10-28 2014-05-14 国立大学法人 東京大学 感染症の疾患マーカー
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
US20140037649A1 (en) * 2010-11-26 2014-02-06 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
GB201102108D0 (en) * 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
EP2756118A4 (en) * 2011-09-16 2015-09-16 Cepheid METHOD FOR DETECTING SEPSIS
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
US10761093B2 (en) 2014-10-09 2020-09-01 Texas Tech University System Microdevice for cell separation utilizing activation phenotype
CN109541235A (zh) * 2018-08-19 2019-03-29 重庆早柒天生物科技股份有限公司 肝素结合蛋白和降钙素原二联检测试剂盒及其制备方法
WO2020218121A1 (ja) 2019-04-24 2020-10-29 公益財団法人がん研究会 癌を検出する方法および検出試薬
CN111208305B (zh) * 2020-02-16 2023-04-25 重庆翼锋生物科技有限公司 Hbp和pct在败血症诊断试剂制备中的用途
CN111951963B (zh) 2020-07-30 2022-09-02 中翰盛泰生物技术股份有限公司 Hbp在covid-19患者的预后风险预警中的应用
WO2022229438A2 (en) * 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Il6 marker panels for early detection of sepsis
WO2022229421A2 (en) * 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Strem1 marker panels for early detection of sepsis
WO2022229435A2 (en) * 2021-04-30 2022-11-03 Roche Diagnostics Gmbh Ngal marker panels for early detection of sepsis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US5962241A (en) * 1989-07-28 1999-10-05 The University Of Arizona Monoclonal antibody detection of proteins on sperm related to fertility
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
RU2200573C2 (ru) 1994-04-21 2003-03-20 Леукотех А/С Связывающий гепарин белок для лечения сепсиса
US5976536A (en) 1995-08-09 1999-11-02 Emory University Neisseria mutants, lipooligosaccharides and immunogenic compositions
US5778895A (en) 1997-01-29 1998-07-14 Uab Research Foundation Method of discriminating bacterial from aseptic meningitis
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
AU2003220034A1 (en) 2002-03-08 2003-09-22 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
US7655480B2 (en) 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
WO2004016653A2 (en) 2002-08-15 2004-02-26 Leukotech A/S Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) or human neutrophil elastase
CA2516836A1 (en) * 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
EP1638530A2 (en) * 2003-06-20 2006-03-29 Royer Biomedical, INC. Drug polymer complexes
WO2005028512A1 (en) * 2003-09-19 2005-03-31 Leukotech A/S Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp)
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
CA2605143A1 (en) * 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
WO2007041623A2 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
FR2894675B1 (fr) 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method

Also Published As

Publication number Publication date
DK2129391T3 (da) 2012-06-11
US20130252347A1 (en) 2013-09-26
US8518648B2 (en) 2013-08-27
JP2010529468A (ja) 2010-08-26
BRPI0812875A2 (pt) 2014-12-09
CN103543271A (zh) 2014-01-29
US9784741B2 (en) 2017-10-10
CN101687023B (zh) 2016-04-20
ES2380875T3 (es) 2012-05-21
WO2008151808A1 (en) 2008-12-18
US20100305185A1 (en) 2010-12-02
CA2690067A1 (en) 2008-12-18
BRPI0812875B1 (pt) 2017-12-05
PT2129391E (pt) 2012-06-06
KR20100021578A (ko) 2010-02-25
BRPI0812875B8 (pt) 2022-07-12
AU2008261252A1 (en) 2008-12-18
ATE548050T1 (de) 2012-03-15
CN101687023A (zh) 2010-03-31
US20140187503A1 (en) 2014-07-03
GB0711327D0 (en) 2007-07-25
SI2129391T1 (sl) 2012-07-31
PL2129391T3 (pl) 2012-09-28
KR101563997B1 (ko) 2015-10-28
EP2129391A1 (en) 2009-12-09
AU2008261252B2 (en) 2013-03-14
EP2129391B1 (en) 2012-03-07
JP5166522B2 (ja) 2013-03-21

Similar Documents

Publication Publication Date Title
CA2690067C (en) A diagnostic method by measuring the levels of heparin-binding protein
US8021836B2 (en) Method of diagnosing infectious disease by measuring the level of soluble TREM-1 in a sample
EP1587409B1 (en) Diagnosis and monitoring of acute coronary syndrome
CN111044725B (zh) 缓激肽介导的病症的评估和治疗
US10126312B2 (en) Diagnostic method for urinary tract infection
US9759720B2 (en) Diagnostic method for bacterial meningitis
Misaki et al. Simultaneous presence of Campylobacter rectus and Cnm-positive Streptococcus mutans in the oral cavity is associated with renal dysfunction in IgA nephropathy patients: 5-year follow-up analysis
CN115975025B (zh) C反应蛋白（crp）检测试剂盒
US20240272178A1 (en) A method for predicting sepsis and septic shock
CN116063482B (zh) C反应蛋白(crp)尿液检测试剂盒
US20220357344A1 (en) Prognosis prediction method of idiopathic pulmonary fibrosis
US20120135425A1 (en) ELISA for Haptoglobin-Matrix Metalloproteinase 9 Complex as a Diagnostic Test for Conditions Including Acute Inflammation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130523

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250423

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401